Nobel Prize for Optogenetics Ignites Race to Commercialize Vision and Brain Therapies
The 2026 Nobel Prize in Physiology or Medicine was awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for developing optogenetics, a technique that uses light to control specific nerve cells. While the prize recognizes the foundational discovery of using light-sensitive proteins from algae to map brain circuits, the immediate commercial impact is concentrated in ophthalmology. Biotech firms are racing to bring optogenetic gene therapies for retinal blindness to market, with Nanoscope Therapeutics and GenSight Biologics advancing clinical trials. Deisseroth’s company, MapLight, is also leveraging the technology for psychiatric drug discovery, though its initial candidates have faced mixed results.